Please enable JavaScript.
Coggle requires JavaScript to display documents.
Kanamycin (MoA (Binding to 30S ribosomal subunit, Inhibit protein…
Kanamycin
MoA
Binding to 30S ribosomal subunit
Inhibit protein synthesis
Change permeability of cell membrane of bacteria
Diffuse through aqueous channels formed by porin proteins
Adverse effects
Ototoxicity
Auditory function
Damage to hearing, sense of balancing & kidneys
Newborn infants
Elderly patients
Neuromuscular blockage
Nephrotoxicity
ADME
Metabolism & Excretion
By glomerular filtration
Half life = 2-3 hrs
Distribution
Do not penetrate into CNS and eyes
Low concentraion
Secretions
Tissues
High concentration
Renal cortex
Perilymph of inner ear
Endolymph
Distribute poorly into adipose tissue
Absorption
Polar cations
Poorly absorbed from GI tract
Absorbed rapidly
Intramuscular sites of injejction
Dosing & monitoring
Short term (7-10days)
Trough (5-10mg/mL)
Peak level (15-30mg/L
Therapeutic uses
Treat gram -ve bacteria infections
E. coli
Proteus species
Klebsilla pneumonia
Limteted spectrum